@article{oai:nagasaki-u.repo.nii.ac.jp:00002510,
 author = {Tanaka, Yoshimasa and Iwasaki, Masashi and Murata-Hirai, Kaoru and Matsumoto, Kenji and Hayashi, Kosuke and Okamura, Haruki and Sugie, Tomoharu and Minato, Nagahiro and Morita, Craig T. and Toi, Masakazu},
 journal = {Scientific Reports},
 month = {Jul},
 note = {Bisphosphonates have benefits in breast cancer and multiple myeloma patients and have been used with adoptive immunotherapy with γδ T cells expressing Vγ2?Vδ2 TCRs. Although treatment with γδ T cells is safe, it has shown limited efficacy. Present bisphosphonates stimulate γδ T cells but were designed to inhibit bone resorption rather than treating cancer and have limited oral absorption, tumor cell entry, and cause bone side effects. The development of phosphate and phosphonate nucleotide prodrugs has led to important drugs for hepatitis C and HIV. Using a similar approach, we synthesized bisphosphonate prodrugs and found that they efficiently limit tumor cell growth. Pivoxil bisphosphonate esters enter cells where esterases convert them to their active acids. The bisphosphonate esters stimulated γδ T cells to secrete TNF-α in response to a variety of tumor cells more efficiently than their corresponding acids. The most active compound, tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1- bisphosphonate (7), specifically expanded γδ T cells and stimulated them to secrete interferon-γ and kill tumor cells. In preclinical studies, combination therapy with compound 7 and γδ T cells prolonged survival of mice inoculated with either human bladder cancer or fibrosarcoma cells. Therefore, bisphosphonate prodrugs could enhance the effectiveness of adoptive cancer immunotherapy with γδ T cells., Scientific Reports, 7, 5987; 2017},
 title = {Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug},
 volume = {7},
 year = {2017}
}